Quotient Clinical begins prostate cancer project for Druggability Technologies
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the initiation of a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate, a marketed drug prescribed in combination with prednisone to patients suffering from metastatic prostate cancer.
Quotient Clinical CEO Mark Egerton Wins EY Entrepreneur of the Year 2015 Award
Quotient Clinical has announced that CEO Mark Egerton has received the EY Entrepreneur of the Year® 2015 Award in the healthcare category for the Midlands region.
Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated, focusing on a next generation selective glucocorticoid receptor antagonist (CORT125134) in development for the treatment of Cushing’s syndrome and certain cancers.
Quotient Clinical reports another successful year of record growth
Quotient Clinical, the Translational Pharmaceutics® Company, announces another strong year of progress and growth. Quotient’s Translational Pharmaceutics platform has been adopted by more than 30 new customers – ranging from top 20 pharma companies to emerging biotech organizations – contributing to a year-on-year increase in revenue of 24%, with similar growth levels anticipated in the next 12 months.
Quotient Clinical completes innovative first-in-human program
Results from the Enabled-First-in-Human® program on an oncology molecule in healthy volunteers published at AACR. Quotient Clinical, the Translational Pharmaceutics® Company, has announced the publication of results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit.
Quotient Clinical announces ADME success in oncology
Quotient Clinical, the Translational Pharmaceutics® Company, has announced contract wins for three further OncoADME programs to support clinical mass balance/ADME investigations in cancer patients. Two of the programs will be undertaken on behalf of US-based biotech organizations and the third is for a top 10 global pharmaceutical company.